drugset / Trial / NCT01617746

Examination of the Bronchoprotective Effect of Endothelin Receptor Blockade in Asthma

NCT01617746

RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this study will be to determine if blockade of endothelin 1 signalling via endothelin receptor A using ambrisentan or dual blockade (A\&B) via bosentan can provide protection against methacholine induced bronchoconstriction in asthma.

Timeline

Start
2012-11
Primary completion
2014-05
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ambrisentan Small molecule 5 mg
Subject Bosentan Other / unclassified 62.5 mg

Indications